-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $80

Benzinga·11/17/2026 18:57:06
Listen to the news
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.